| 1. KEYTRUDA is a registered trademark of Merck & Co., Inc. KYMRIAH is a registered trademark of Novartis Pharmaceuticals Corporation.
Grab Sources Here: CTXR Presentation. -----
5 Critical Potential Catalysts To Consider - Key (Nasdaq: CTXR) Details
There are 5 potential catalysts that could attract attention to CTXR and should be looked at understood closely.
Here's what to know:
#1. Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025.
The anticipated commercial launch of LYMPHIR™, an FDA-approved immunotherapy for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), represents a significant milestone for Citius Pharmaceuticals, the parent company of Citius Oncology.
This transition will position Citius Pharmaceuticals as a fully integrated commercial-stage organization, highlighting its capacity to advance therapies from development to market.
Comprehensive preparations—including completed commercial-scale manufacturing, robust supply chain agreements, and engagement with top-tier distribution partners—ensure that LYMPHIR will be accessible to patients across the United States, both in major cancer centers and community settings.
Citius Oncology’s collaboration with key opinion leaders, patient advocacy groups, and the broader clinical community has informed a patient-centered approach to the launch, while targeted marketing strategies and educational resources are set to support healthcare providers and patients.
The inclusion of LYMPHIR in the National Comprehensive Cancer Network (NCCN) guidelines and the assignment of a permanent J-code facilitate efficient reimbursement and coverage, further supporting broad adoption.
For Citius Pharmaceuticals, LYMPHIR’s launch will not only expand its oncology portfolio but also strengthen its reputation as an innovative force in specialty pharmaceuticals.
This milestone enhances operational capabilities, opens new partnership opp's, and sets the stage for future growth and development within the oncology sector.
#2. A Limited Float Could Amplify Market Volatility Potential.
Market watchers may note that CTXR’s float is on the fairly low side.
Based on data from Yahoo Finance, the company’s float is approximately 16.52Mn shares.
Why does this matter? A low float can often translate to greater volatility potential.
With great volatility potential comes the need for watching CTXR with a very close eye.
#3. A Strategic Partnership Could Empower LYMPHIR's Future Commercial Launch Success.
Citius Oncology, a subsidiary of Citius Pharmaceuticals, has strengthened its commercialization strategy by signing an exclusive agreement with EVERSANA to support the anticipated Q4 2025 U.S. launch of LYMPHIR, its FDA-approved therapy for relapsed or refractory cutaneous T-cell lymphoma.
Through this partnership, Citius gains access to EVERSANA’s integrated commercialization platform, including medical, data, and channel management services.
This collaboration enhances launch readiness, reduces execution risks, and positions Citius Pharma for sustained growth and value creation in the oncology market.
#4. An Analyst Target Suggests Triple-Digit Potential Upside.
According to reports from Benzinga and TipRanks, D. Boral Capital analyst Jason Kolbert has set a $6 target on CTXR.
From Friday's closing valuation, this target suggests over 300% upside potential.
Could this suggest that CTXR is undervalued from current chart levels?
#5. Citius Oncology AI Platform Enhances LYMPHIR Launch Preparedness And Impact.
Citius Oncology, a subsidiary of Citius Pharmaceuticals, Inc., has launched an advanced AI platform to empower its commercial team ahead of LYMPHIR’s debut for cutaneous T‑cell lymphoma.
The proprietary, continuously learning system analyzes real-world data to identify prescribers, refine targeting, and personalize engagement.
By integrating predictive insights with marketing performance analytics, the tool boosts efficiency, optimizes provider education, and improves patient access.
This strategic innovation strengthens Citius’ market position, accelerates heal-thcare outreach, and amplifies the precision and impact of its future LYMPHIR launch. -----
Coverage is officially running on Citius Pharmaceuticals, Inc. (Nasdaq: CTXR). Be on the lookout for updates coming your way.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 10/20/2025 and ending on 10/20/2025 to publicly disseminate information about (CTXR:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid four thousand USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid nineteen thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (CTXR:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/ctxr-vepvl/#details | 
